Download or read book Therapeutic targeting Of MDSC in the tumor and immune microenvironment written by Erika Adriana Eksioglu and published by Frontiers Media SA. This book was released on 2023-12-18 with total page 131 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Myeloid Derived Suppressor Cells and Cancer written by David Escors and published by Springer. This book was released on 2016-03-15 with total page 109 pages. Available in PDF, EPUB and Kindle. Book excerpt: The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
Download or read book Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy written by Pawel Kalinski and published by Springer. This book was released on 2017-12-22 with total page 271 pages. Available in PDF, EPUB and Kindle. Book excerpt: The tumor microenvironment has become a very important and hot topic in cancer research within the past few years. The tumor microenvironment is defined as the normal cells, molecules, and blood vessels that surround and feed a tumor cell. As many scientists have realized, studying the tumor microenvironment has become critical to moving the field forward, since there are many players in a tumor’s localized and surrounding area, which can significantly change cancer cell behavior. There is a dual relationship wherein the tumor can change its microenvironment and the microenvironment can affect how a tumor grows and spreads. Tumor Microenvironment in Cancer Progression and Cancer Therapy aims to shed light on the mechanisms, factors, and mediators that are involved in the cancer cell environment. Recent studies have demonstrated that in addition to promoting tumor progression and protecting tumor cells from the spontaneous immune-mediated rejection and different forms of cancer therapeutics, tumor microenvironment can also be a target and mediator of both standard and newly-emerging forms of cancer therapeutics. Thus, the dual role of the tumor microenvironment is the integral focus of the volume. The volume highlights the bi-directional interactions between tumor cells and non-malignant tumor component during tumor progression and treatment. It also focuses on the three groups of the reactive tumor component: stromal cells, blood vessels and the infiltrating immune cells. These three groups are discussed under the lens of their role in promoting tumor growth, shielding the tumor from rejection and from standard forms of cancer therapies. They are emerging as targets and mediators of standard and new forms of potential therapy.
Download or read book Targeting the Tumor Microenvironment for a More Effective and Efficient Cancer Immunotherapy written by Salem Chouaib and published by Frontiers Media SA. This book was released on 2020-07-02 with total page 196 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Targeting Myeloid Cells to Fight Cancer written by Maija Hollmén and published by Frontiers Media SA. This book was released on 2020-01-24 with total page 150 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Tumor Microenvironment written by Peter P. Lee and published by Springer Nature. This book was released on 2020-03-25 with total page 326 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book addresses the biological processes relevant to the immune phenotypes of cancer and their significance for immune responsiveness, based on the premise that malignant cells manipulate their surroundings through an evolutionary process that is controlled by interactions with innate immune sensors as well as the adaptive recognition of self/non-self. Checkpoint inhibitor therapy is now an accepted new form of cancer treatment. Other immuno-oncology approaches, such as adoptive cell therapy and metabolic inhibitors, have also shown promising results for specific indications. Immune resistance is common, however, limiting the efficacy of immunotherapy in many common cancer types. The reasons for such resistance are diverse and peculiar to the immune landscapes of individual cancers, and to the treatment modality used. Accordingly, approaches to circumvent resistance need to take into account context-specific genetic, biological and environmental factors that may affect the cancer immune cycle, and which can best be understood by studying the target tissue and correlated systemic immune markers. Understanding the major requirements for the evolutionary process governing human cancer growth in the immune-competent host will guide effective therapeutic choices that are tailored to the biology of individual cancers.
Download or read book Cancer Stem Cell Resistance to Targeted Therapy written by Cristina Maccalli and published by Springer. This book was released on 2019-06-04 with total page 256 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book represents an up-dated summary of the state of the art of the characterization of cancer stem cell/ cancer initiating cell (CSC/CIC) properties. An overview of the definition and biological properties of CSCs/CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies is provided. It also discusses limitations in the achievement of a definitive biological characterization of CSCs/CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs/CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells. This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs/CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs/CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients.
Download or read book Targeted Cancer Immune Therapy written by Joseph Lustgarten and published by Springer Science & Business Media. This book was released on 2009-10-09 with total page 340 pages. Available in PDF, EPUB and Kindle. Book excerpt: Stimulation of the immune system’s ability to control and destroy tumors cont- ues to be the goal of cancer immune therapy; but the scope has rapidly expanded; approaches are constantly updated; new molecules are continually introduced; and immune mechanisms are becoming better understood. This book has no intention of covering every aspect of immune therapy but rather focuses on the novelty of cancer immune therapy in an attempt to give readers an opportunity to absorb the new aspects of immune therapy from a single source. In this regard, three areas were selected: cytokine immune therapy, cell-based immune therapy, and targeted immune therapy. In each of these three sections, only the novel aspects of immune therapy were described instead of attempting to cover any historical achievement. In the first section, Cytokine Immune Therapy, the IL12 family, IL18, IL21, IL24, IL28, and IL29 were emphasized in regard to the an- tumor function and application in treating tumors. Most of these selected cyt- ines were discovered in last 10 years. In the second section, Cell-based Immune Therapy, the focus was engineering potent immune regulatory or effector cells such as dendritic cells, T cells, and stem cells. Cell engineering design is primarily based on the increased understanding of the interaction of tumor antigen-presenting cells, antigen- specific effector cells, and the tumor microenvironment.
Download or read book Roles of Tumor Recruited Myeloid Cells in Immune Evasion in Cancer written by Sergei Kusmartsev and published by Frontiers Media SA. This book was released on 2021-10-18 with total page 202 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Tumor Induced Immune Suppression written by Dmitry I. Gabrilovich and published by Springer Science & Business Media. This book was released on 2008-01-01 with total page 304 pages. Available in PDF, EPUB and Kindle. Book excerpt: This monograph, for the first time, presents a comprehensive overview of different mechanisms of immune dysfunction in cancer as well as therapeutic approaches to their correction. It discusses a number of new mechanisms that have never been discussed in a monograph before: T-cell inhibitory molecules, regulatory tolerogenic DCs, and signaling pathways in antigen-presenting cells involved in T-cell tolerance. There is now a pressing need to discuss the already described and newly emerging mechanisms to see how they can be put together in a more or less cohesive structure and how they can help to improve immune response to tumors.
Download or read book Cancer Immunotherapy written by Sandra Demaria and published by Elsevier Inc. Chapters. This book was released on 2013-06-04 with total page 34 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumors that become clinically apparent have invariably developed ways to escape immune control. The mechanisms of escape are multiple and diverse and do not necessarily require the loss by tumor cells of expression of antigens recognized by the immune system. More commonly, tumor-specific T cells are rendered dysfunctional by a number of soluble and cell surface-bound molecules that are produced or modified by the action of cancer cells or suppressive and regulatory immune cells recruited to the tumor. Overall, the obstacles that prevent tumor rejection are active at several levels, affecting T-cell priming, functional differentiation, recruitment to the tumor, survival and effectors’ function inside the tumor. The multifaceted nature of these immunosuppressive networks represents a formidable obstacle to the success of immunotherapy. Nevertheless, the recent achievements of therapeutics targeting key checkpoint receptors highlight the great potential of strategies that are based on selective disruption of immunosuppressive networks.
Download or read book Cancer Immunotherapy written by Gang Chen and published by Elsevier Inc. Chapters. This book was released on 2013-06-04 with total page 38 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cancer is managed by surgery, radiation therapy, and systemic drug therapies. Drug therapies include endocrine manipulation, single- or multi-agent chemotherapy, and monoclonal antibody therapy. Targeted small molecules that specifically capitalize on vulnerabilities that map to signaling pathways indispensible for tumor growth and progression are now also a part of the standard of cancer care. More recently, rapidly accumulating data illustrates a critical role for the immune system in the response to chemotherapy, radiation (the abscopal effect), and novel targeted cancer therapies. Integrating immune-based therapies strategically with established and novel cancer therapeutics should generate a robust antitumor effect that takes advantage of the strengths of their individual modes of action and also leverages potential immunologic synergies.
Download or read book Enhancing Immune Therapy for Cancer by Targeting Myeloid Derived Suppressor Cells written by Andrew Robert Stiff and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: While some of the mechanisms that cause impaired NK cell and T cell function are linked to processes inherent to tumor cells such as cytokine production and metabolic alterations it is also clear that cancer is linked to the expansion of multiple immune suppressive cell populations such as regulatory T cells (Treg), tumor associated macrophages (TAMs), and myeloid derived suppressor cells (MDSC).
Download or read book Immunotherapy of Hepatocellular Carcinoma written by Tim F. Greten and published by Springer. This book was released on 2018-08-22 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
Download or read book Tumor Induced Immune Suppression written by Dmitry I. Gabrilovich and published by Springer Science & Business Media. This book was released on 2014-02-10 with total page 471 pages. Available in PDF, EPUB and Kindle. Book excerpt: Tumor-Induced Immune Suppression - Prospects and Progress in Mechanisms and Therapeutic Reversal presents a comprehensive overview of large number of different mechanisms of immune dysfunction in cancer and therapeutic approaches to their correction. This includes the number of novel mechanisms that has never before been discussed in previous monographs. The last decades were characterized by substantial progress in the understanding of the role of the immune system in tumor progression. Researchers have learned how to manipulate the immune system to generate tumor specific immune response, which raises high expectations for immunotherapy to provide breakthroughs in cancer treatment. It is increasingly clear that tumor-induced abnormalities in the immune system not only hampers natural tumor immune surveillance, but also limits the effect of cancer immunotherapy. Therefore, it is critically important to understand the mechanisms of tumor-induced immune suppression to make any progress in the field and this monograph provides these important insights.
Download or read book The Heterogeneity of Cancer Metabolism written by Anne Le and published by Springer. This book was released on 2018-06-26 with total page 186 pages. Available in PDF, EPUB and Kindle. Book excerpt: Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.
Download or read book Defining the Immune Microenvironment in Sarcoma written by Marie Kostine and published by . This book was released on 2018 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Local control with adequate surgery is the cornerstone of sarcoma treatment. However, most sarcoma lack effective systemic therapies in case of advanced disease, emphasizing an unmet medical need for new therapeutic targets. The recent success of immunotherapy in epithelial malignancies raises the question whether such therapies, and which ones, would be applicable in sarcomas. As a prerequisite for therapeutic applications, we characterized the immune microenvironment in three sarcoma subtypes potentially candidate to immunotherapy: 1) In chondrosarcoma, PD-L1 expression was exclusively found in nearly 50% of the dedifferentiated subtype, in association with immune-infiltrating cells and HLA class I expression. These data provide rationale for including such patients in clinical trials with PD-1/PD-L1-targeted therapies. 2) In osteosarcoma, we observed a high density of tumor-infiltrating T cells in metastatic lesions compared to primary tumors and local relapses. Furthermore, PD-L1 positivity in almost half of metastases while mainly negative in the associated primary tumors, emphasises the dynamics of an adaptive mechanism of immune escape. Enhancing the preexisting immune response in metastatic lesions using T-cell-based immunotherapy may offer clinical benefit. 3) In leiomyosarcoma, HLA class I molecules were strongly upregulated and PD-L1 expression found in 30% of high-grade tumors, which were also highly infiltrated with CD163+ immunosuppressive macrophages. CD163+ was found to be an independent poor prognostic factor for overall survival, indicating the need for assessing a macrophage-targeted approach in this tumor type, as single agent or in combination with anti PD-1/PD-L1agents.
